From NuGOwiki
The NuGOwiki Metabolite Database is a joint initiative of NuGO and HMDB
| Taxonomy Navigation Box; search by |
|
All Metabolites | Biochemical | Nutritional | Functional | Metabolic Pathways | Diseases | Phenotypes | Physiological Processes | Protein |
| IL12 | |
|---|---|
| [[Image:{{{Image}}}|thumb|220px|2D structure for IL12]] | |
| Chemical Name | |
| Chemical Formula | |
| CAS Number | |
| Chemical Information | |
| Biochemical Taxonomy | |
| Functional Taxonomy | |
| Nutritional Taxonomy | |
| Metabolic Pathways | |
| Biofluid Location | |
| Tissue Location | |
| Normal Biofluid Concentrations | |
| Normal Tissue Concentrations | |
| Diseases / Conditions Related to Nutrition | |
| Other (Monogenic Disorders) | |
| Abnormal Biofluid Concentrations | |
| Abnormal Tissue Concentrations | |
| Physiological Processes | |
| Authors: | L. Pellis |
| Affiliations: | TNO, the Netherlands |
Contents |
Introduction
Human interleukin 12
Interleukin 12 (IL-12, also called IL12 p70) consists of 2 subunits; p40 is the 40 kDa subunit (IL12B) and p35 is the 35 kDa subunit (IL12A). It is produced mainly by B-cells and to a lesser extent by T-cells. The most powerful inducers of IL-12 are bacteria, bacterial products, and parasites. It has been shown to augment natural killer-cell mediated cytotoxicity in a number of conditions, including patients with hairy cell leukemia, and it has been shown to inhibit the growth of a variety of experimental tumors in vivo as well as to have anti-angiogenic effects in vivo, which are, at least in part, mediated by IFN-gamma. IL-12 therefore seems to be a potential candidate also for the treatment of angiogenesis-dependent malignancies.
Rodent interleukin 12
IL-12 is produced mainly by B-cells and to a lesser extent by T-cells. The most powerful inducers of IL-12 are bacteria, bacterial products, and parasites. It has been shown to augment natural killer-cell mediated cytotoxicity in a number of conditions. The ability of IL-12 to induce the synthesis of IFN-gamma and to stimulate the proliferation of resting peripheral cells may be of interest also. IL-12 has been shown to inhibit the growth of a variety of experimental tumors in vivo and to have anti-angiogenic effects in vivo, which are, at least in part, mediated by IFN-gamma. IL-12 therefore seems to be a potential candidate also for the treatment of angiogenesis-dependent malignancies.
Biological Function
Hetrodimeric cytokine IL12, consists of IL12A and IL12B chain. IL12 can act as a growth factor for activated T and NK cells, enhance the lytic activity of NK/lymphokine-activated killer cells, and stimulate the production of IFN-gamma by resting PBMC.
IL12A
Recommended name:
Interleukin-12 subunit alpha, IL-12A
Alternative name(s):
IL-12 subunit p35
Cytotoxic lymphocyte maturation factor 35 kDa subunit, CLMF p35
NK cell stimulatory factor chain 1, NKSF1
IL12B
Recommended name:
Interleukin-12 subunit beta, IL-12B
Alternative name(s):
IL-12 subunit p40
Cytotoxic lymphocyte maturation factor 40 kDa subunit, CLMF p40
NK cell stimulatory factor chain 2,NKSF2
Catabolism
Diseases / Conditions Related to Nutrition
Associated decreased protein/metabolite profile
Associated increased protein/metabolite profile
Other (Monogenic) Disorders
Nutritional Information
Drivers for biological variation
Vulnerable groups
Other resources
Links
IL12A
IL12B